Abatacept: from a budget impact model to cost-effectiveness analysis – data from RCT and real life by Benucci M, Damiani A, Manfredi M, Infantino M, Grossi V, Li Gobbi F

Get full text

Therapeutic Potential of Ixekizumab in the Treatment of Ankylosing Spondylitis: A Review on the Emerging Clinical Data by Benucci M, Damiani A, Li Gobbi F, Grossi V, Infantino M, Manfredi M, Niccoli L, Cantini F

Get full text

Correlation between HLA haplotypes and the development of antidrug antibodies in a cohort of patients with rheumatic diseases by Benucci M, Damiani A, Li Gobbi F, Bandinelli F, Infantino M, Grossi V, Manfredi M, Noguier G, Meacci F

Get full text

Personalization of biologic therapy in patients with rheumatoid arthritis: less frequently accounted choice-driving variables by Niccoli L, Nannini C, Blandizzi C, Mantarro S, Mosca M, Di Munno O, Goletti D, Benucci M, Li Gobbi F, Cassarà E, Kaloudi O, Cantini F

Get full text

Correlations between immunogenicity, drug levels, and disease activity in an Italian cohort of rheumatoid arthritis patients treated with tocilizumab by Benucci M, Meacci F, Grossi V, Infantino M, Manfredi M, Bellio E, Bellio V, Li Gobbi F, Bazzichi L, Moscato P, Caputo D, Saviola G, Talotta R, Sarzi-Puttini P, Atzeni F

Get full text

Immunoglobulin A antibodies to oxidized collagen type II as a potential biomarker for the stratification of spondyloarthritis from rheumatoid arthritis by Vinci, C, Infantino, M, Raturi, S, Tindell, A, Topping, LM, Strollo, R, Amital, H, Shoenfeld, Y, Gertel, S, Grossi, V, Manfredi, M, Rutigliano, IM, Bandinelli, F, Li Gobbi, F, Damiani, A, Pozzilli, P, Mcinnes, IB, Goodyear, CS, Benucci, M, Nissim, A